DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

Nektar Therapeutics (NASDAQ: NKTR)

company name or ticker

Progenics, Nektar Still Halted; FDA Advisory Committee Expected To Conclude Thursday

Top Healthcare Movers For June 9, 2014

Small Phamaceuticals Rallying Following FDA Report

Friday's ETF Movers: ILF, FBT

Bullish Two Hundred Day Moving Average Cross - NKTR

Celldex: The Race Leader In Glioblastoma Multiforme

Orexigen Will Run: Here's Why

NKTR September 20th Options Begin Trading

Nektar Therapeutics: The Time Is Nigh

Here's What You Need to Know About Nektar Therapeutics' Upcoming Catalysts

Nektar Therapeutics has been an underperforming biotech this year, falling 4.14% year to date. Yet, this diverse biotech has three major catalysts coming down the pike over the next nine months that could radically change its fortunes.
See More Articles...